ASLAN Pharmaceuticals Ratios and Metrics

Market cap in millions TRY. Fiscal year is January - December.

Millions TRY. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2020
Period Ending	Aug '25 Aug 13, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2020
Last Close Price	246.00	27.56	-	-	-	-	Upgrade
Debt / Equity Ratio	0.80	0.83	0.56	0.34	0.97	1.92	Upgrade
Debt / EBITDA Ratio	1.57	1.21	0.55	0.40	0.91	2.80	Upgrade
Asset Turnover	0.50	0.65	1.04	0.88	0.80	0.55	Upgrade
Quick Ratio	0.57	0.69	0.64	0.62	0.41	0.11	Upgrade
Current Ratio	2.39	2.39	2.95	3.59	1.94	1.37	Upgrade
Return on Equity (ROE)	29.77%	43.41%	89.51%	81.88%	90.35%	22.63%	Upgrade
Return on Assets (ROA)	19.30%	27.92%	48.65%	41.81%	37.30%	13.26%	Upgrade
Return on Capital (ROIC)	23.22%	33.05%	59.92%	48.16%	39.99%	13.80%	Upgrade
Return on Capital Employed (ROCE)	39.60%	52.80%	76.00%	70.90%	86.30%	53.10%	Upgrade
Dividend Yield	0.13%	1.14%	-	-	-	-	Upgrade
Payout Ratio	9.19%	3.64%	5.03%	4.09%	11.07%	12.04%	Upgrade
Buyback Yield / Dilution	-170.00%	-136.00%	-	-66.67%	-	-49.99%	Upgrade
Total Shareholder Return	-169.87%	-134.86%	-	-66.67%	-	-49.99%	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.